This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Whitney, C. W. Articles by Liao, S.-Y. Search for Related Content PubMed PubMed Citation Articles by Whitney, C. W. Articles by Liao, S.-Y. Social Bookmarking                            What's this?

Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study

From the Department of Obstetrics and Gynecology, Thomas Jefferson University College of Medicine, Philadelphia, PA; University of Utah and Radiation Therapy Department, Latter Day Saints Hospital, Salt Lake City, UT; Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, and Gynecologic Oncology, Albany Medical College, Albany, NY; Division of Gynecologic Oncology, University of Texas Medical Branch, Galveston, TX; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, and Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC; and Department of Pathology, University of California Medical Center at Irvine, Orange, CA.

Address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market St, Philadelphia, PA 19107

ABSTRACT

PURPOSE: In 1986, a protocol comparing primary radiation therapy (RT) plus hydroxyurea (HU) to irradiation plus fluorouracil (5-FU) and cisplatin (CF) was activated by the Gynecologic Oncology Group (GOG) for the treatment of patients with locally advanced cervical carcinoma. The goals were to determine the superior chemoradiation regimen and to quantitate the relative toxicities.

METHODS: All patients had biopsy-proven invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix. Patients underwent standard clinical staging studies and their tumors were found to be International Federation of Gynaecology and Obstetrics stages IIB, III, or IVA. Negative cytologic washings and para-aortic lymph nodes were required for entry. Patients were randomized to receive either standard whole pelvic RT with concurrent 5-FU infusion and bolus CF or the same RT plus oral HU.

RESULTS: Of 388 randomized patients, 368 were eligible; 177 were randomized to CF and 191 to HU. Adverse effects were predominantly hematologic or gastrointestinal in both regimens. Severe or life-threatening leukopenia was more common in the HU group (24%) than in the CF group (4%). The difference in progression-free survival (PFS) was statistically significant in favor of the CF group (P = .033). The sites of progression in the two treatment groups were not substantially different. Survival was significantly better for the patients randomized to CF (P = .018).

CONCLUSION: This study demonstrates that for patients with locally advanced carcinoma of the cervix, the combination of 5-FU and CF with RT offers patients better PFS and overall survival than HU, and with manageable toxicity.

NOTES

The full text of this article is also available at http://www.asco.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Domingo, V. Lorvidhaya, R. de los Reyes, T. SyOrtin, P. Kamnerdsupaphon, C. Lertbutsayanukul, E. Vito-Cruz, E. Tharavichitkul, K. Jin, M. Yoshihara, et al. Capecitabine-Based Chemoradiotherapy with Adjuvant Capecitabine for Locally Advanced Squamous Carcinoma of the Uterine Cervix: Phase II Results Oncologist, August 1, 2009; 14(8): 828 - 834. [Abstract] [Full Text] [PDF]

				P. P. Connell and S. Hellman Advances in Radiotherapy and Implications for the Next Century: A Historical Perspective Cancer Res., January 15, 2009; 69(2): 383 - 392. [Full Text] [PDF]

				Chemoradiotherapy for Cervical Cancer Meta-Analysi Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials J. Clin. Oncol., December 10, 2008; 26(35): 5802 - 5812. [Abstract] [Full Text] [PDF]

				A. Nogueira-Rodrigues, C. C. do Carmo, C. Viegas, F. Erlich, C. Camisao, K. Fontao, R. Lima, D. Herchenhorn, R. G. Martins, G. M. Moralez, et al. Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6324 - 6329. [Abstract] [Full Text] [PDF]

				P. Petignat and M. Roy Diagnosis and management of cervical cancer BMJ, October 13, 2007; 335(7623): 765 - 768. [Full Text] [PDF]

				B. J. Monk, K. S. Tewari, and W.-J. Koh Multimodality Therapy for Locally Advanced Cervical Carcinoma: State of the Art and Future Directions J. Clin. Oncol., July 10, 2007; 25(20): 2952 - 2965. [Abstract] [Full Text] [PDF]

				P. G. Rose, S. Ali, E. Watkins, J. T. Thigpen, G. Deppe, D. L. Clarke-Pearson, and S. Insalaco Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., July 1, 2007; 25(19): 2804 - 2810. [Abstract] [Full Text] [PDF]

				R. Pearcey, Q. Miao, W. Kong, J. Zhang-Salomons, and W. J. Mackillop Impact of Adoption of Chemoradiotherapy on the Outcome of Cervical Cancer in Ontario: Results of a Population-Based Cohort Study J. Clin. Oncol., June 10, 2007; 25(17): 2383 - 2388. [Abstract] [Full Text] [PDF]

				N. Fuwa, T. Kodaira, H. Tachibana, T. Nakamura, and T. Daimon Dose Escalation Study of Nedaplatin with 5-Fluorouracil in Combination with Alternating Radiotherapy in Patients with Head and Neck Cancer Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 161 - 167. [Abstract] [Full Text] [PDF]

				Y. Niibe, K. Hayakawa, S. Tsunoda, T. Kanai, M. Imai, M. Arai, T. Arai, M. Kawaguchi, T. Jobo, Y. Hamada, et al. Phase II Study of Radiation Therapy Combined with Weekly Nedaplatin in Locally Advanced Uterine Cervical Carcinoma: Kitasato Gynecologic Radiation Oncology Group (KGROG 0501) Jpn. J. Clin. Oncol., January 4, 2007; (2007) hyl153v1. [Abstract] [Full Text] [PDF]

				P. J. Eifel Chemoradiotherapy for Cervical Cancer: What Next? J. Clin. Oncol., November 20, 2005; 23(33): 8277 - 8279. [Full Text] [PDF]

				R. Lanciano, A. Calkins, B. N. Bundy, G. Parham, J. A. Lucci III, D. H. Moore, B. J. Monk, and D. M. O'Connor Randomized Comparison of Weekly Cisplatin or Protracted Venous Infusion of Fluorouracil in Combination With Pelvic Radiation in Advanced Cervix Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., November 20, 2005; 23(33): 8289 - 8295. [Abstract] [Full Text] [PDF]

				H Yamashita, K Nakagawa, M Tago, K Shiraishi, N Nakamura, and K Ohtomo Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix Br. J. Radiol., September 1, 2005; 78(933): 821 - 826. [Abstract] [Full Text] [PDF]

				E. Barranger, C. Coutant, A. Cortez, S. Uzan, and E. Darai Sentinel node biopsy is reliable in early-stage cervical cancer but not in locally advanced disease Ann. Onc., August 1, 2005; 16(8): 1237 - 1242. [Abstract] [Full Text] [PDF]

				C. Haie-Meder, B. Fervers, E. Fondrinier, M. Haugh, C. Lhomme, and J. P. Guastalla SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004 Ann. Onc., July 1, 2005; 16(7): 1100 - 1108. [Abstract] [Full Text] [PDF]

				W. Park, Y. J. Park, S. J. Huh, B. G. Kim, D. S. Bae, J. Lee, B. H. Kim, J. Y. Choi, Y. C. Ahn, and D. H. Lim The Usefulness of MRI and PET Imaging for the Detection of Parametrial Involvement and Lymph Node Metastasis in Patients with Cervical Cancer Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 260 - 264. [Abstract] [Full Text] [PDF]

				M Garipagaoglu, F Kayikcioglu, M F Kose, M Adli, K H Gulkesen, Z Kocak, and G Tulunay Adding concurrent low dose continuous infusion of cisplatin to radiotherapy in locally advanced cervical carcinoma: a prospective randomized pilot study Br. J. Radiol., July 1, 2004; 77(919): 581 - 587. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]

				P. J. Eifel, K. Winter, M. Morris, C. Levenback, P. W. Grigsby, J. Cooper, M. Rotman, D. Gershenson, and D. G. Mutch Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01 J. Clin. Oncol., March 1, 2004; 22(5): 872 - 880. [Abstract] [Full Text] [PDF]

				A. Duenas-Gonzalez, C. Lopez-Graniel, A. Gonzalez-Enciso, L. Cetina, L. Rivera, I. Mariscal, G. Montalvo, E. Gomez, J. de la Garza, G. Chanona, et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation Ann. Onc., August 1, 2003; 14(8): 1278 - 1284. [Abstract] [Full Text] [PDF]

				J. J. Zarba, A. V. Jaremtchuk, P. Gonzalez Jazey, M. Keropian, R. Castagnino, C. Mina, and G. Arroyo A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma Ann. Onc., August 1, 2003; 14(8): 1285 - 1290. [Abstract] [Full Text] [PDF]

				P. G. Rose Combined-Modality Therapy of Locally Advanced Cervical Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 211s - 217. [Abstract] [Full Text] [PDF]

				A. D. Colevas, J. M. Brown, S. Hahn, J. Mitchell, K. Camphausen, and C. N. Coleman Development of Investigational Radiation Modifiers J Natl Cancer Inst, May 7, 2003; 95(9): 646 - 651. [Full Text] [PDF]

				L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, and D. Shasha Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes Oncologist, December 1, 2002; 7(6): 492 - 508. [Abstract] [Full Text] [PDF]

				J. V. Fiorica Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan Oncologist, October 1, 2002; 7(90005): 36 - 45. [Abstract] [Full Text] [PDF]

				A. Duenas-Gonzalez, C. Lopez-Graniel, A. Gonzalez-Enciso, A. Mohar, L. Rivera, A. Mota, R. Guadarrama, G. Chanona, and J. de la Garza Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies Ann. Onc., August 1, 2002; 13(8): 1212 - 1219. [Abstract] [Full Text] [PDF]

				M. Friedlander and M. Grogan Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer Oncologist, August 1, 2002; 7(4): 342 - 347. [Abstract] [Full Text] [PDF]

				J. D. Bloss, J. A. Blessing, B. C. Behrens, R. S. Mannel, J. S. Rader, A. K. Sood, M. Markman, and J. Benda Randomized Trial of Cisplatin and Ifosfamide With or Without Bleomycin in Squamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., April 1, 2002; 20(7): 1832 - 1837. [Abstract] [Full Text] [PDF]

				P. G. Rose and B. N. Bundy Chemoradiation for Locally Advanced Cervical Cancer: Does It Help? J. Clin. Oncol., February 15, 2002; 20(4): 891 - 893. [Full Text] [PDF]

				R. Pearcey, M. Brundage, P. Drouin, J. Jeffrey, D. Johnston, H. Lukka, G. MacLean, L. Souhami, G. Stuart, and D. Tu Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix J. Clin. Oncol., February 15, 2002; 20(4): 966 - 972. [Abstract] [Full Text] [PDF]

				S. M. Schwartz, J. R. Daling, K. A. Shera, M. M. Madeleine, B. McKnight, D. A. Galloway, P. L. Porter, and J. K. McDougall Human Papillomavirus and Prognosis of Invasive Cervical Cancer: A Population-Based Study J. Clin. Oncol., April 1, 2001; 19(7): 1906 - 1915. [Abstract] [Full Text] [PDF]

				M. F. Janicek and H. E. Averette Cervical Cancer: Prevention, Diagnosis, and Therapeutics CA Cancer J Clin, March 1, 2001; 51(2): 92 - 114. [Abstract] [Full Text] [PDF]

				W. A. Peters III, P. Y. Liu, R. J. Barrett II, R. J. Stock, B. J. Monk, J. S. Berek, L. Souhami, P. Grigsby, W. Gordon Jr, and D. S. Alberts Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix J. Clin. Oncol., April 1, 2000; 18(8): 1606 - 1613. [Abstract] [Full Text] [PDF]

				R. G. Pearcey, I. G. Mohamed, J. Hanson, M. S. Piver, M. Morris, P. J. Eifel, P. G. Rose, and B. N. Bundy Treatment of High-Risk Cervical Cancer N. Engl. J. Med., August 26, 1999; 341(9): 695 - 697. [Full Text]

				P. J. Eifel Concurrent Chemotherapy and Radiation: A Major Advance for Women With Cervical Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1334 - 1334. [Full Text] [PDF]